Evidence map›Paper›PMID 37022563›Full record

ReviewCurrent pain and headache reports2023

The Use of Oxytocin for the Treatment of Opioid Use Disorder.

Amber N Edinoff, Saveen Sall, Lauryn G Honore, Ross M Dies, Alexa R Zaheri, Saurabh Kataria, Eric D Jackson, Sahar Shekoohi, Elyse M Cornett, Kevin S Murnane and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Novel neurotherapeutic targets for substance use disorders: Neuroplasticity, neuroinflammation, gasotransmitters and non-canonical organ systems.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  2. Review
  3. Are We Getting High Cause the Thrill is Gone?Journal of addiction psychiatry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Amber N EdinoffDepartment of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Saveen SallDepartment of Psychiatry and Behavioral Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Lauryn G HonoreSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Ross M DiesSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Alexa R ZaheriSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Saurabh KatariaDepartment of Neurology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Eric D JacksonCollege of Medicine-Phoenix, University of Arizona, Phoenix, AZ, 85004, USA.
Sahar ShekoohiDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA. sahar.shekoohi@lsuhs.edu.
Elyse M CornettLouisiana Addiction Research Center, Shreveport, LA, 71103, USA.
Kevin S MurnaneLouisiana Addiction Research Center, Shreveport, LA, 71103, USA.
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, 95211, USA.
Alan D KayeLouisiana Addiction Research Center, Shreveport, LA, 71103, USA.
Louisiana State University Health Sciences Center Shreveport · USHarvard University · USPhoenix College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nearly 27 million people have an opioid use disorder (OUD) according to the 2016 Global Burden of Disease study, most of which occur in the US where opioids are a common class of medication used to treat acute and chronic pain. In 2016 alone, more than 60 million patients had at least one prescription for opioids filled or refilled. Over the past decade, prescription rates have risen astronomically and have created an epidemic in the US dubbed the "opioid crisis." In this regard, there has been an increase in overdoses and OUD diagnoses. Several studies have found dysregulation of balance between several neurotransmitters involved in the neural circuitry that subserves several behavioral domains, such as reward recognition, motivation, learning, and memory, affect, stress, and executive function, that contribute to the manifestation of craving. On the horizon is a new treatment approach consisting of the neuropeptide oxytocin, which may be involved in the overlapping mechanisms of stable attachment formation and coping with stress. Through this mechanism, it can shift processing from novelty and reward-seeking to an appreciation of familiarity and thus reduce stress and increase resilience in the face of addiction. It has been hypothesized that there is a connection between the glutaminergic and oxytocinergic systems, making oxytocin a possible therapeutic agent in reducing drug-induced actions seen in OUD patients. This manuscript will review the potential and feasible use of oxytocin in treating OUD.

Indexed as

Chronic PainDrug OverdoseOpioid-Related DisordersAnalgesics, OpioidHumansOxytocinAnalgesics, OpioidOxytocinAddictionDependenceOpioidsOpioid use disorderOxytocin

Identifiers

PMID37022563
OpenAlexW4362657038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.